Pegaptanib for the treatment of age-related macular degeneration
- 1 September 2006
- journal article
- review article
- Published by Elsevier in Experimental Eye Research
- Vol. 83 (3) , 615-619
- https://doi.org/10.1016/j.exer.2006.02.010
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUMRetina, 2005
- A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular EdemaPublished by Elsevier ,2005
- New Treatments for Age-Related Macular DegenerationOphthalmology, 2005
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Pegaptanib in Exudative Age-Related Macular DegenerationDrugs, 2005
- PegaptanibDrugs, 2005
- Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2004
- Genistein Suppressed Upregulation of Vascular Endothelial Growth Factor Expression by Cobalt Chloride and Hypoxia in Rabbit Retinal Pigment Epithelium CellsJournal of Ocular Pharmacology and Therapeutics, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2002